Navigation Links
Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
Date:7/20/2010

low or undetectable.  No serious or severe adverse events were attributable to ARC-4558 treatment and the topical formulation was well-tolerated at the site of skin application.  

"The top-line data reported today for ARC-4558 provide strong support for Arcion's fundamental approach of applying therapies topically to relieve neuropathic pain by targeting nerve signaling at the level of the skin," said James Campbell, M.D., President and CEO of Arcion. "Through this study, we identified a simple, predictive clinical test to identify non-responders to ARC-4558, which should enable us to optimize subject enrollment in future studies.  Based on our successful End of Phase 2 meeting with the FDA, we believe ARC-4558 will be the first PDN treatment indicated to treat patients who have demonstrable functional nociceptors in the skin.  The full Phase 2b results will be submitted for future peer review and we look forward to advancing the ARC-4558 program in Phase 3 studies."

Michael C. Rowbotham, M.D., Adjunct Professor of Neurology and Anesthesia and Director, UCSF Pain Clinical Research Center, commented, "Painful diabetic neuropathy is frequently a debilitating condition that severely impacts a patient's quality of life and ability to carry out normal day-to-day functions.  There are approved therapies to control the pain, but issues of tolerability and efficacy seriously limit their usefulness.  A novel mechanism-based topical treatment with a low liability of systemic side effects has promise to advance significantly the treatment of this condition and improve the quality of life for a large number of patients."

About the Phase 2b Trial

The Phase 2b study included an adaptive trial design and enrolled a total of 180 adult patients with PDN. Pati
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
3. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Nile Therapeutics Completes Dosing of Phase II Study
6. Cornerstone Therapeutics Announces Management Change
7. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
8. InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
9. Global Melanoma Therapeutics Industry
10. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
11. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... WAYNE, Pa. , April 1, 2015 /PRNewswire/ ... fully integrated specialty pharmaceutical company focused on developing, ... the pricing of an offering of $60.0 million ... due 2020 (the "notes") in a private placement ... under the Securities Act of 1933, as amended ...
(Date:4/1/2015)... SAN CLEMENTE, Calif. , April 1, 2015 /PRNewswire/ ... residents in the United States ... out amongst their resident colleagues. In its inaugural year, ... and 50 of the top nominations were narrowed to ... voting process that saw over 10,000 votes from colleagues ...
(Date:4/1/2015)... CREEK, Calif. , April 1, 2015  For ... huge difference.  When this is the case, having the ... No one understands this truth better than software solutions ... laboratory management software QATrax.  Recently, the company announced the ... very enthusiastic response from clients. ...
Breaking Medicine Technology:Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 2Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 3Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 4TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 Baby Bellies ... providing the latest information on the top products and ... set the Guinness World Records title for "Mommy Moments” ... of the 1st annual Baby Bellies & Beyond Expo ... and the Guinness World Record will commence at 11:00am ...
(Date:4/1/2015)... Bethesda, MD, Alexandria, VA (PRWEB) April 01, 2015 ... Pathology (ASCP), the College of American Pathologists (CAP), ... American Society of Clinical Oncology (ASCO) today released ... the use of molecular marker testing for patients ... guideline will help establish standard molecular marker testing, ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might ... latest post discusses Teen Violence Related to Substance Abuse. ... Violence Awareness Month, the substance abuse treatment center has ... parents identify if there may be problems with their ... or alcohol. , “People learn how to establish healthy ...
(Date:4/1/2015)... 01, 2015 Like a mosaic slowly ... scientific understanding of the potential causes of rosacea. April ... National Rosacea Society (NRS) to educate the public on ... disorder now estimated to affect more than 16 million ... research on rosacea through its patient-funded research grants program, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Dr. ... and Distinguished Teaching Professor of the Department of Plastic ... other doctors to review reports of blindness resulting from ... surgery . The group published their study, along with ... Reconstructive Surgery journal. , "We began to see increasing ...
Breaking Medicine News(10 mins):Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
... international comparison of the care of patients with rectal ... use of chemotherapy and radiotherapy between European countries. ... by ECCO the European CanCer Organisation compared ... and The Netherlands who were diagnosed with rectal cancer ...
... options for patients with bone metastases from advanced prostate ... Phase III study of an alpha-pharmaceutical in these patients ... to research reported today (Saturday) at the 2011 European ... Chris Parker, Consultant Clinical Oncologist at the Royal Marsden ...
... , FRIDAY, Sept. 23 (HealthDay News) -- People,s bodies ... new study suggests black men who live in areas of ... have vitamin D deficiency than whites who live in the ... current vitamin D recommendations need to change. "This study shows ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) ... women be vaccinated against human papillomavirus, a sexually transmitted disease ... recommendation does not extend to boys and young men. ... over whether males also should be vaccinated for human papillomavirus, ...
... Sept. 23 (HealthDay News) -- Researchers have identified five new ... attack and coronary artery disease -- the most common cause ... a new study. The international consortium said their ... develop new treatments for the condition. In conducting the ...
... [Nairobi, 23 September 2011] East Africa is fighting the ... the region through the Leishmaniasis East Africa Platform (LEAP) ... therapy (SSG&PM) which is cheaper and nearly halves the ... injections to 17 days. East African endemic countries are ...
Cached Medicine News:Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 3Health News:Scientists ID More Genes Linked to Heart Disease 2Health News:New treatment for kala azar, the most deadly parasitic disease after malaria 2Health News:New treatment for kala azar, the most deadly parasitic disease after malaria 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: